Skip to content
Reference draft · Awaiting editorial review
inside your peptides.
Search
← Home/Peptides A–Z/BPC-157
inside your peptidescompound file · healing
the compound index

BPC-157

Studied for bladder pain and cystitis, tendon and ligament repair and gut lesion protection. A 15-amino-acid fragment of a protein in human gastric juice, described by a Zagreb pharmacology group in 1993 and sold since as a research chemical.

categoryhealing
clinical evidenceanimal only
community adoptionvery high
uses graded4
sources14
last reviewed24 Aug 2026
compound file

The answer, first. A 15-amino-acid fragment of a protein in human gastric juice, described by a Zagreb pharmacology group in 1993 and sold since as a research chemical. The strongest evidence is for bladder pain and cystitis, graded C — small or open-label human only.

The only prospective human series: twelve women, one intravesical 10 mg injection, all twelve scoring 5/5 on global response 5.

Single arm, no control, no blinding, every patient a responder. Every other use — tendon and ligament repair, gut lesion protection, muscle injury recovery — grade D or E: animal or mechanism data with no controlled human outcome.

What it is used for

Every use graded on its own evidence, not the compound as a whole. 4 outcomes, ranked by what the human record supports.

#outcome · human · animal · gradewhat the best evidence actually shows
01Bladder pain and cystitis1 open series, n=12 · rodent cystitis modelsgrade CThe only prospective human series: twelve women, one intravesical 10 mg injection, all twelve scoring 5/5 on global response 5. Single arm, no control, no blinding, every patient a responder.
02Tendon and ligament repairno trial · 10+ rodent studiesgrade DThe most-cited use. Transected rat Achilles recovered on 10 µg/kg intraperitoneally daily: higher load-to-failure, higher Young's modulus, better function through day 14 1. No human trial.
03Gut lesion protectionno trial · deepest part of the filegrade DWhere the molecule started and where the rodent record runs deepest. Intraperitoneal dosing cut colonic damage and myeloperoxidase activity dose-dependently in rats, 0.0001 to 10 nmol/kg 3. No human trial.
04Muscle injury recoveryno trial · crush and transection modelsgrade DCrushed rat gastrocnemius healed better on BPC-157 given intraperitoneally or as a cream, daily for 14 days, on function and on creatine kinase 4. Rodent only. No human trial.
gradewhat it means
ARegulatory approval, or multiple adequately-powered trials agreeing with each other
BAt least one well-powered human randomised trial, with the direction replicated
CSmall or open-label human trials only
DAnimal or mechanism data only, with no controlled human outcome
EA claim the human trials have already killed

How it works

The proposed mechanism, in three steps. A mechanism is a reason to run a trial, never a substitute for one.

1targetProposed to act through the nitric oxide system and VEGF receptor 2, not a dedicated receptor. Described from gastric juice in 1993 613.
2signalIn rat hind-limb ischaemia it raised VEGFR2 expression and drove internalisation, activating the VEGFR2-Akt-eNOS pathway 6.
3effectNew vessels reach injured tissue faster in rodents 6. Tendon fibroblasts migrate and survive oxidative stress better in culture 2.

What it does not do

Claims the current record does not support. Worth knowing before you set expectations.

not supported by the evidence
  • Human trials support it. A systematic review to June 2024 found 36 studies: 35 preclinical, one clinical and retrospective. No clinical safety data 7.
  • 60 to 70% of users report healing. No such dataset exists. Vendor blogs attribute invented percentages to a community record that holds nothing of the kind.
  • Anecdotal recovery proves it works. Tendinopathy recovers on its own. Placebo arms gained 13 of 100 VISA-P points by six months and 27 by twelve 9.
  • Strong animal data means it works. Animal-to-human concordance is poor. Tirilazad cut infarct volume 29% in animal stroke models and worsened outcomes in patients 14.

Where to buy BPC-157

Graded on the documents, not the price. The board is ranked by what each vendor publishes; the price is shown and never weighted. Every price re-checked at the vendor’s own page on 8 Sep 2026.

rank 1 of 3 · the next lab · disclosed
Grade A−. Certificate in hand.

The next lab holds BPC-157 in Los Angeles and publishes the certificate on its current lot. Five measures on it: identity by LC-MS, purity by HPLC-UV, the measured fill, endotoxin by USP <85> in duplicate, a PCR microbial screen. Tested at Freedom Diagnostics under accession TheN2608200838, which you can look up yourself. Sterility is not on the panel, here or anywhere on this board.

lotNL-BP-6H01
label10 mg
measured fill12.21 mg
purity99.59%
price$55 · $5.50/mg
first vialWELCOME15 · −15%
Enter the next lab ↗Open the certificate ↗Compare 3 vendors →Cycle cost →
Commercial disclosure: Inside Your Peptides is maintained by our business team. Scale Peptides is a marketing site used by our sales team. Links to Scale Peptides and The Next Lab promote our business, not independent supplier recommendations. Read the disclosure policy.

How it is used

What published protocols administered, and what the community reports doing. Descriptive on both counts, and never a recommendation.

routeSubcutaneous injection is the musculoskeletal default. Oral capsules are discussed for gut complaints. The rodent studies used intraperitoneal dosing 134.
formatLyophilised powder in 5 or 10 mg vials, reconstituted with bacteriostatic water. Capsules and a stabilised arginate variant also sold.
published dosesNo human dose has ever been published for tendon, muscle or gut. The rodent studies dosed 10 µg/kg, 10 ng/kg or 10 pg/kg intraperitoneally once daily 1, and 0.0001 to 10 nmol/kg in the colitis model 3. The one human series injected 10 mg into a bladder wall, once 5.
human pharmacokineticsNo human pharmacokinetic data published. In rats and dogs the half-life is under 30 minutes 8.
reported conventionsAs reported on r/Peptides, r/bpc_157, MESO-Rx and AnabolicMinds, 2018-2026: runs framed in weeks with breaks rather than continuous use. Injection near the injury or anywhere, depending on which camp. Oral formats reserved for gut complaints, single compounds preferred over pre-mixed blends. Convention, not guidance.
commonly paired withTB-500

This site does not publish protocols to follow. The doses above are what studies administered or what users report, stated as facts about the literature and the market. How protocols are structured, mixing and storage and the reconstitution calculator cover the arithmetic.

What to expect

Where a trial measured it, the trial. Where only the community reports it, that is said out loud.

onsetNo human trial has measured timing for any musculoskeletal or gut outcome. The rat Achilles study assessed at days 1, 4, 7, 10 and 14 1. As reported on forums, musculoskeletal claims cluster at two to six weeks, anecdote on a curve that rises anyway 9.
most common reportAs reported: nothing. Broad side-effect threads skew toward no issues, and the healing claims that follow carry no counterfactual.
adverse effectsNo trial rates exist. The two human pilot reports logged no adverse events across fourteen subjects 510. As reported across Reddit, MESO-Rx and YouTube: a recurring minority cluster of acute anxiety at days 1-3, anhedonia and flattening at weeks 1-2. Also fatigue and palpitations, gut irritation with pre-mixed blends.
the stop signalAs reported, the standing community rule after a bad reaction is to pause, restart lower, and avoid pre-blended stacks so the culprit can be isolated. No published protocol defines a stop signal.

Approval and status

What regulators and sport bodies have actually said, separately from what the evidence shows.

approvalNot approved in any jurisdiction. Sold as a research chemical.
FDANominated for compounding, then withdrawn. FDA says it lacks sufficient information to know whether the drug would cause harm in humans 11.
sport [WADA]Prohibited under S0, non-approved substances, at all times 12.
sold asresearch chemical

Covered in depth

These reports grade BPC-157 at length and carry their own verified reference lists.

BPC-157: The Evidence, Graded Honestly

The most-searched healing peptide on the market rests almost entirely on animal data. What the studies show, what they don't, and why WADA bans it anyway.

Check the vial

The grade above describes a molecule studied under controlled conditions. It says nothing about the powder in a particular vial.

That gap is the one part of this market a reader can actually close. How to read a certificate of analysis covers the five measures in five minutes, and the 2026 audit grades vendors on the documents they publish against a rubric printed in full.

Questions we get

What is BPC-157 used for?

People buy it for tendon and ligament injury, gut complaints, and muscle tears. The rodent literature covers all three and reports benefit in nearly every model published. The gut work is the deepest part of that file and the tendon work is the most cited.

None of it is a human outcome. There is no published randomised human trial of BPC-157 for any indication, and no published human pharmacokinetics. No dose in a person has ever been characterised.

How is BPC-157 used?

Descriptively, because no protocol has been published for a person. The rodent studies injected it intraperitoneally, once daily, at 10 µg/kg down to 10 pg/kg. The one human series injected 10 mg into a bladder wall in a single procedure.

As reported on forums, subcutaneous injection is the musculoskeletal default and oral capsules are used for gut complaints. Runs are framed in weeks with breaks, and single compounds are preferred over blends. Convention, not guidance.

How long does BPC-157 take to work?

Nobody has measured it in a person. The rat Achilles study assessed healing on days 1, 4, 7, 10 and 14, and the crush-injury study ran 14 days. Community reports cluster around two to six weeks for musculoskeletal complaints.

That is exactly the window in which untreated tendon injury improves on its own. Placebo arms in patellar tendinopathy trials gained 13 of 100 points by six months. Anecdote cannot separate the two.

Are there any published randomised human trials of BPC-157?

No. A systematic review screening to June 2024 found 36 includable studies, 35 preclinical and one clinical and retrospective. It reported no clinical safety data. Two small pilot reports have appeared since, both single-arm and uncontrolled.

The absence is economic as much as scientific: the sequence has been public since 1993, so no sponsor can own the answer. This site annotates that separately as trial-blocked. A blocked D is still a D.

Is BPC-157 banned in sport?

Yes. It falls under section S0 of the WADA Prohibited List. S0 covers substances with no current approval from any governmental regulatory health authority for human therapeutic use. That makes it prohibited at all times, in and out of competition.

USADA states there are no human clinical trials establishing efficacy for any diagnosis or treatment. A therapeutic use exemption is unlikely, it adds, because permitted alternatives exist. S0 is a statement about approval status, not about danger.

References

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21:976-83. PMID 14554208
  2. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110:774-80. PMID 21030672
  3. Veljaca M, et al. BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J Pharmacol Exp Ther. 1995;272:417-22. PMID 7815358
  4. Novinscak T, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. Surg Today. 2008;38:716-25. PMID 18668315
  5. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30:12-17. PMID 39325560
  6. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95:323-333. PMID 27847966
  7. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21:485-495. PMID 40756949
  8. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022;13:1026182. PMID 36588717
  9. Previtali D, et al. Placebo Effect in the Treatment of Patellar Tendinopathy and Its Influencing Factors. Orthop J Sports Med. 2024;12:23259671241258477. PMID 39221039
  10. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31:20-24. PMID 40131143
  11. FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of 22 April 2026. fda.gov
  12. USADA. BPC-157: Experimental Peptide Creates Risk for Athletes. usada.org
  13. Sikirić P, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. J Physiol Paris. 1993;87:313-27. PMID 8298609
  14. Perel P, et al. Comparison of treatment effects between animal experiments and clinical trials: systematic review. BMJ. 2007;334:197. PMID 17175568

Commercial disclosure: Inside Your Peptides is maintained by our business team. Scale Peptides is a marketing site used by our sales team. Links to Scale Peptides and The Next Lab promote our business, not independent supplier recommendations. Read the disclosure policy.